Bristol-Myers Squibb Co.

Aldo Donati is the Principal and Founder of Compass Pharmaceuticals LLC. Mr. Donati has extensive international business experience in the pharmaceutical industry and has held executive positions in Sales/Marketing, Business Development/Licensing and General management, with among others, Bristol-Myers Squibb, Sigma-Tau and King Pharmaceuticals. He has negotiated licensing and distribution agreements, as well as managed commercial operations, alliances and Our Partners & Clientships in Europe, Latin America, Asia and the United States. Fluent in English, Italian, Portuguese and Spanish, Mr. Donati maintains a worldwide network of contacts throughout the pharmaceutical industry, the medical community, Trade Organizations and Teaching Institutions. He graduated from the University of Florence in Italy in International Relations Business from the School of Political Sciences Cesare Alfieri.

James M. Cornelius. Mr. Cornelius, our Chairman of the board of directors, is currently the Chairman of the board of directors and Chief Executive Officer of BMS and he has served in such a role since February 2008. Mr. Cornelius served as the Chief Executive Officer, including serving as Interim Chief Executive Officer, of BMS since September 2006 when he ended his retirement. Mr. Cornelius served as the Interim Chief Executive Officer and Chairman of the board of directors for Guidant Corporation from November 2005 to April 2006 when it was acquired by Boston Scientific Corporation, at which point Mr. Cornelius retired. He served as Guidant s Non-Executive Chairman of the board of directors from August 2000 until November 2005. Mr. Cornelius is a director and chairman of the audit committee of The DIRECTV Group and he is also a director and chairman of the compensation committee and member of the audit committee of Given Imaging Ltd.

Todd H. Kasdan, M.D. is a licensed board-certified physician. Dr. Kasdan served his internship and residency at Loyola University Medical Center. He earned his M.D. degree from Loyola University's Stritch School of Medicine, and was awarded a B.S. degree in physiology from Michigan State University. In addition to his clinical practice, Dr. Kasdan is on the speakers bureau for Pfizer Pharmaceuticals Inc., Astra Zeneca PLC, and Abbott Labs; serves as a consultant to or sits on the advisory board of Eli Lilly & Company, Bristol-Myers Squibb Company, Forest Pharmaceuticals Inc., and Sanofi Synthelabo; receives grant support from Novartis Pharmaceuticals AG; and, is involved in clinical research trials with Janssen Pharmaceutica LP. Additionally, Dr. Kasdan sits on Cornell Companies' (NYSE - CRN) Pharmacy & Therapeutics committee.

Dr. Dixon serves as the President of Global Marketing and Chief Marketing Officer at Bristol-Myers Squibb Company, a position she has held since joining the company in December 2001. She also serves on the Executive Committee of Bristol-Myers. From 1996 to November 2001, Dr. Dixon held executive management positions at Merck & Company, most recently serving as the Senior Vice President of Marketing. Prior to her employment at Merck, Dr. Dixon held executive management positions with Osteotech and Centocor and various positions at SmithKline in marketing, regulatory affairs and project management. Dr. Dixon was appointed to the DENTSPLY Board of Directors in July 2005.

Jon Cobb has served as Vice President and General Manager for Dimension, the 3D Printing business unit of Stratasys since January of 2002. Mr. Cobb joined the company as Vice President of Marketing in August of 1995. Before joining the company, Mr. Cobb served as Vice President of Sales and Marketing for Westec Security, Inc. and has held various Sales and Marketing Management positions with Lockheed Martin's Calcomp Division. Mr. Cobb received a B.S.degree from the University of Wisconsin, Madison.

Stanley D. Burhans. Mr. Burhans, our Vice President and Controller, has been continuously employed by Mead Johnson or BMS since 1992 in various capacities. Before assuming his current position, Mr. Burhans served as Vice President, Finance of Mead Johnson since February 2006. From July 2005 to February 2006, Mr. Burhans served as Senior Director, International Finance of Mead Johnson and from June 2003 to July 2005, he served as Senior Director, U.S. Finance of Mead Johnson.

Elliott Sigal, M.D., Ph.D., has been a member of the company's Executive Committee since 2001. Previously, Sigal served as senior vice president of Global Clinical and Pharmaceutical Development and co-chair of the Brand Development Operating Committee.

Sandra Leung. Ms. Leung, one of our directors, is currently Senior Vice President and General Counsel of BMS and she has served in such a role since February 2007. From September 2006 to February 2007, Ms. Leung served as Vice President, Corporate Secretary and Acting General Counsel of BMS and from June 2002 to September 2006, she served as Vice President and Corporate Secretary of BMS.

Eitan Sharir is the President and founder of Dynamic Achievement Group. Eitan holds a Bachelor of Commerce degree in Business Economics and a Post-Graduate degree in International Marketing and General Management. For the past 10 years, he has worked with thousands of business professionals in key areas such as Business Transformation, Visionary Leadership and other business areas focused on achieving superior performance results. He has had extensive international experience as a High Performance Catalyst, Consultant and Coach and through extensive research into human behavior and change strategies, he has provided leading-edge techniques that facilitate superior performance in organizations and individuals' careers. Eitan works with leading organizations, such as Avis Rent a Car, Orca Bay, Sheraton Vancouver Wall Centre, Bristol-Myers Squibb, TELUS, PCL Constructors Canada, Creo, Crystal Decisions, Scotia Bank, Sara-Lee Corporation, Otis Elevators, Colgate-Palmolive and Mercedes-Benz. He also personally coaches top business executives in achieving both their personal and corporate objectives. He has also enjoyed a successful business career culminating as Managing Director in an organization specializing in Information Technology.

Louis Sullivan served as U.S. Secretary of Health and Human Services from 1989 to 1993. Prior to and following his service as HHS Secretary, he was President of Morehouse School of Medicine, which he now serves as President Emeritus. He is co-chair of The Presidential Advisory Council on HIV/AIDS. A graduate of Morehouse College, he earned his medical degree from Boston University, and is certified in internal medicine and hematology. The recipient of 45 honorary degrees, he served on the faculties of the medical schools at Harvard, Seton Hall, and Boston universities before arriving at Morehouse in 1975. He was also the founding president of the Association of Minority Health Professions Schools.

Béatrice Cazala was appointed to her current position in March 2009. She was previously President, Europe and Asia Pacific. In her new role, she continues her legacy of leadership and results across Europe and assumes responsibilities for Global Commercialization. Under Beatrice’s leadership, Global Commercialization will be increasingly focused on market access, customer interface and integration of assets from our alliances, acquisitions and partnerships. Béatrice joined the company in 1982 as a product manager based in France. In 1987, she moved to the Worldwide Strategic Product Planning group in the U.S. as a director, and was later promoted to vice president. In 1991, she returned to France to hold senior commercial positions until 1994, when she was appointed vice president and general manager of UPSA France. In 2000, she became senior vice president and general manager, Pharma/UPSA France and, in 2002, she was appointed senior vice president, Northern Europe, based in the UK. Prior to joining Bristol-Myers Squibb, Béatrice spent five years at laboratories Cassenne (Aventis). She holds an MBA from the Ecole Supérieure de Commerce et d’Administration des Entreprises (Rouen, France).

Carlo de Notaristefani is responsible for the Bristol Myers Squibb Technical Operations organization, which meets the company’s complex supply chain challenges. Technical Operations plays a critical role in the company’s transformation into an increasingly agile and productive discoverer, developer and provider of innovative new medicines. Carlo's responsibilities for Global Support Functions encompass Global Facilities and Engineering, Global Procurement and Information Management Shared Services. Carlo joined Bristol-Myers Squibb in early 2004 from Aventis Pharmaceuticals, where he was senior vice president of Global Finishing Solids. He spent nearly 20 years of his career at Aventis and its predecessors, Hoechst Marion Roussel and Marion Merrel Dow. At Bristol-Myers Squibb, Carlo was appointed to the position of senior vice president of Global Manufacturing Operations in June 2004 and he assumed the position of president of Technical Operations in September 2004. Carlo is a certified professional engineer and holds a doctoral degree in engineering from the University of Naples, Italy. Through the course of his career, Carlo has moved across the Atlantic Ocean five times. He now resides happily in New Jersey. He and his wife have two grown sons.

Bob Zito leads strategic communications with a focus on building the Bristol-Myers Squibb corporate brand. He also oversees the Bristol-Myers Squibb Foundation. Bob has guided the successful Together we can prevail brand campaign, which focuses on Bristol-Myers Squibb’s mission to help patients prevail against serious disease. Lou DiMaggio and other survivors, some famous, some not, tell their equally powerful and intimate stories in television spots and Web videos. “Capturing the emotion of that partnership, and that struggle, is at the center of our company’s mission,” Bob says. "The work the people of this company do every day and the difference it makes to people with serious diseases is inspiring." A former sports writer, Bob coaches his team to use a storytelling approach to effectively communicate the mission, news and philanthropy of the company. His team includes public relations, marketing communications, advertising, the Internet, internal communications and philanthropy. "We have a lot of great stories to tell about our past, and the future is even more exciting as we transform into a leading next-generation BioPharma company." Before joining Bristol-Myers Squibb in 2004, Bob worked in the entertainment and financial industries. As Sony’s vice president of corporate communications from 1990 to 1994, he rebranded the company as a global entertainment organization following Sony’s purchase of both CBS Records and Columbia Pictures. Then, during a 10-year career as executive vice president of the New York Stock Exchange, he was credited with building the NYSE’s brand into one of the most respected in the world. He also devised the strategy of using the opening and closing bells as televised news events, and allowed networks to broadcast from the trading floor. After the tragic events of September 11, 2001, Bob joined the board of the FDNY Foundation. He helped found the NYSE Fallen Heros Fund and is a founding member of Cento Amici, a non-profit group that provides scholarships to New Jersey students. A native of Bayonne, New Jersey, Bob graduated from St. Peter’s Prep in Jersey City and later established a scholarship for students from his hometown in his father’s memory. Bob earned his bachelor's degree from Fairfield University and completed Harvard's Advanced Management Program in International Studies. He is married, has three daughters, and on weekends he and his family can be found on the soccer field watching his youngest daughter compete.

Anthony McBride is charged with integrating the company’s Human Resources programs and practices with its business priorities and strategies. He is a strategic leader with a commitment to leadership development and organizational change. Anthony joined Bristol-Myers Squibb in 1995 as associate director, Human Resources Development, Worldwide Medicines. Since then, he has held numerous leadership positions including director, Leadership Development, and a variety of vice president positions in Europe, International Medicines, U.S. Pharmaceuticals and, most recently, Worldwide Pharmaceutical Commercial Operations. He began his current position as senior vice president, Human Resources, in April 2008. “Our mission as a company is to extend and enhance human life. That includes improving the lives of our own families as well. We take pride in our mission and our recognition as a Top 100 company for working mothers and a Top 10 company for executive women,” Anthony says. “The work we do, the quality of our people, and the many opportunities to learn and grow, make Bristol-Myers Squibb an engaging and highly satisfying place to be.” Anthony is moving forward with a 10-year $324 million project to transform and support our company’s global human resource functions. “We will become more streamlined in our operations,” he says. “This will help us manage talent within our organization and have an integrated view into our employee population and workforce data. This is integral to helping us better serve our customers and our strategic transformation to a BioPharma leader.” Before joining Bristol-Myers Squibb, Anthony was a consultant in the New York office of Personnel Decisions Inc., where he specialized in executive coaching, talent selection, management development, and organizational development consulting to Fortune 500 companies. Born and raised in Houston, Texas, Anthony earned a bachelor’s degree in psychology from the University of Texas, Austin, and both his master’s and doctorate degrees in Industrial/Organizational Psychology from Texas A&M University. Anthony lives in New Jersey with his wife and their two children. He enjoys photography, music and travel.

Brian Daniels is senior vice president, Global Development & Medical Affairs, and a member of the Management Council, the company’s most senior leadership group. In this position, he helps drive the company’s focus on science and medicine as a central strategy of our next-generation BioPharma vision. “Pharmaceutical R&D is a long and complex process,” says Brian. “My role is to make the internal workings as simple as possible so that good, bright people can make substantial contributions to patient care. Our goal is to produce medicines that change the standard of care in a meaningful way for physicians, provide economic value to payers and, most importantly, extend and enhance the lives of patients.” Brian joined Bristol-Myers Squibb in 2000 as vice president of the Immunology, Pulmonary and Dermatology therapeutic area, where he provided strategic oversight and led the early development of compounds including ORENCIA and belatacept. In 2002, Brian was promoted to vice president, Full Development, providing leadership to the development of six key clinical programs including REYATAZ and BARACLUDE. He also led efforts to improve productivity and to standardize and integrate the global execution of clinical trials as vice president of Global Development Operations. He was appointed senior vice president, Global Clinical Development in 2004, and to his current position in March 2008. Prior to joining Bristol-Myers Squibb, Brian spent four years at Merck Research Laboratories in clinical research, where he held the role of senior director, Pulmonary and Immunology. He has also worked in clinical research at Genentech. Brian is married with two teenage children, a boy and a girl. Next to spending time with his family, what he enjoys most is gardening. “It’s sort of like simplified drug development,” he says. “It takes a lot of careful tending to develop a great garden. But when you’re successful, it’s a beautiful thing.” Brian holds bachelor’s and master’s degrees in biology from the Massachusetts Institute of Technology and a medical degree from Washington University School of Medicine. He received training in internal medicine at New York Hospital and in rheumatology at the University of California in San Francisco.

John Celentano has responsibility for the countries in our Emerging Markets Strategy -- Brazil, Russia, India, China and Turkey, as well as Asia Pacific and Japan. John was previously Senior Vice President, Strategy and Productivity Transformation, which he held from March 2008 to March 2009. John was responsible for the company's Productivity Transformation Initiative. "A more competitive Bristol-Myers Squibb means that we will be able to bring more innovative products to market faster, he says." Ultimately, the beneficiaries of our transformation are patients and customers, employees and shareholders." John joined Bristol-Myers Squibb as a sales representative in 1982. He advanced through the Bristol-Myers Squibb ranks in sales, market research and marketing. In 2000, he became vice president and general manager, Northern Europe, and in 2002 was promoted to president of our operations in Latin America and Canada. Three years later, he was named president, Health Care Group, with responsibility for the Mead Johnson Nutrition, ConvaTec and Medical Imaging divisions. John earned his bachelor’s degree from the University of Delaware in 1982 and an MBA from Drexel University in 1989. He is married and has three children.

Dr. Annalisa Jenkins studied at the Medical College of St. Bartholomew's Hospital in London. Following her undergraduate studies, she earned her medical degree from the University of London. She then accepted a commission with the British Royal Navy and embarked on a nine-year career as a medical officer. During that time, she saw active service in the Gulf conflict in 1991 and was recognized as the first female physician in the British Royal Navy ever to serve at the front line in conflict. In 1997, after becoming a cardiologist, she joined Bristol-Myers Squibb and began a career in pharmaceutical research and development. Dr. Jenkins served in positions of increasing global responsibility until she was appointed as Chief Medical Officer for Europe, the Middle East, and Africa. Then, in 2006, Dr. Jenkins was promoted to Vice President, Global Development, before assuming her current role in 2008.

Dr. Nicholas Dracopoli is Vice President of Clinical Discovery Technologies at Bristol-Myers Squibb. Previously, he was Vice President at Genos Biosciences, a joint venture between Sequana Therapeutics and the Memorial Sloan-Kettering Cancer Center, and Vice President of Molecular Genetics at Sequana Therapeutics. Dr Dracopoli obtained his B.Sc. and Ph.D. degrees from the University of London, and completed post doctoral fellowships at the Memorial Sloan-Kettering Cancer Center and the Massachusetts Institute of Technology (MIT). Subsequently, he served as an Assistant Director at the Whitehead/MIT Genome Center, and as a Section Chief at the National Center for Human Genome Research at the NIH before moving to the biotechnology industry. Dr Dracopoli has authored >70 scientific publications, and has extensive experience in the fields of cancer research and molecular biology. Currently, Dr Dracopoli is leading the pharmacogenomics program at Bristol-Myers Squibb which is focusing in the areas of oncology and cardiovascular disease.

Mr. Hooper received his M.B.A. in Business Administration and a Bachelor's degree in Law from the University of South Africa. He joined BMS as a General Manager, BMS Australia/New Zealand in 1996. He was then promoted to Managing Director, United Kingdom and Ireland, followed by his role of Vice President and General Manager for Northern Europe. In 2001 Tony became President, Asia-Pacific, Middle East & Southern Africa, International Medicines. From 2001 to 2002, he was President, Intercontinental, International Medicines. In 2002 to 2004, Tony was President, Europe, ME & Africa, Worldwide Medicines Group. Presently, Tony is President, US Pharmaceuticals, Worldwide Medicines Group. Prior to joining BMS, Tony was the Assistant Vice President of Marketing for Wyeth Laboratories International. He also worked for Lederle International in New Jersey, Lederle Laboratories in South Africa and South African Cyanamid Pty. Ltd. Mr. Hooper is an active member in a number of non-profit associations. He resides in Hopewell, New Jersey with his wife, Norma and two children.

Dr. Frank Shen is Executive Director in Exploratory Development, Global Biometric Sciences at Bristol-Myers Squibb. He joined the pharmaceutical industry in 1989 and worked at Wyeth-Ayerst Research as a Research statistician until 1993. He then joined Biometrics Research group at Merck as a manager. Frank joined Bristol-Myers Squibb (BMS) in 1996 as Associate Director and has progressed with increasing responsibilities since then. Dr. Shen has been named a Fellow of the American Statistical Association, and elected as the 2004 President of the International Chinese Statistical Association (ICSA). Frank is currently a member of the Clinical Leadership Committee (CLC) of PhRMA and chairs the Biostatistics and Data Management Technical Group under CLC that leads biometric interactions between pharmaceutical industry and the FDA.

Christele Hadjadj recently joined the CSCMP-NYC as the Hospitality Chair. She has over 14 years of experience in Sales & Marketing, Strategic Sourcing, Logistics, Planning and Supply Chain Management. She is currently the Biologics Supply Chain Director at Bristol-Myers Squibb Company. Christele holds a B.A. in International Management from ESCEM, France, and a MBA from Lehigh University. She is CSCP certified.

Daniel G. Mannix, PhD, is Group Director, Global Regulatory Affairs, Europe, for Bristol-Myers Squibb and is based at the company's European R&D Headquarters in Braine l'Alleud, Belgium. Previously, he was Global Vice President of Regulatory Affairs with GE Healthcare (formerly Amersham Health).

After an academic career in Internal Medicine, Dr. Petrin started his industry career in the early nineties as the Bristol-Myers Squibb Medical Director for Eastern Europe. He was instrumental in introducing GCP trials into several countries of the region, such as Russia, Czech Republic, Hungary, Poland, etc. He spent 10 years with BMS in roles of increasing responsibility and before leaving BMS to start his own company, he was responsible for Bristol-Myers Squibb regulatory affairs in Asia Pacific, Latin America, Middle East, and Africa. Currently, he also serves as President, Pharmaceutical Regulatory Services, Inc., offering regulatory and medical consulting services in the field of global drug development. He teaches a postgraduate course in Global Regulatory Affairs at the Temple University School of Pharmacy in Philadelphia. He graduated from the University of Ljubljana Medical School and is Board Certified in Internal Medicine. He is a Member of the American College of Physicians and several other medical associations.

Mr. Batres role and responsibilities include financial and operational planning. He has over 25 years of global pharmaceutical management experience with a record of achievements in finance, demand and supply chain management, operations and business planning, and information technology. During his career in the pharmaceutical industry, Mr. Batres has held various senior management positions in finance and operations including international responsibilities encompassing Latin America, Asia-Pacific, Europe and Africa. Mr. Batres combines extensive experience in operations with strong skills in financial planning and analysis. He has held positions including Financial Controller of Bristol-Myers Squibb, Europe and Vice President of Global Demand and Supply Chain Management at Bristol-Myers Squibb, USA.

Alex brings with him 21 years of experience in the consumer product industry. With his impressive retail trade marketing background, coupled with strong leadership, interpersonal and planning abilities, he definitely contributes to further strengthen Norrizon's results-oriented team. Alex's business acumen comes from having worked in a variety of roles with Encore Sales Limited, Bristol-Myers Squibb, and Shoppers Drug Mart. In addition to his sales and retail responsibilities, for the past twelve years Alex has been an active board member of a charitable organization based in Toronto.

Having previously worked with patients, students, healthcare practitioners, and peers, Amanda brings a wide range and variety of experience, specifically in virology, to this company. Her career spanned both clinical practice and work within the pharmaceutical sector as a Medical Science Liaison for Bristol-Myers Squibb Virology. Most recently, she had served as Director of Pharmacy for StatScript, a specialty pharmacy in Minneapolis, Minnesota, where she was involved in a variety of aspects of patient care for HIV, hepatitis C, organ-transplant patients, and other patients with chronic diseases. In this position, she managed participation in a national study that evaluated delivery devices for Fuzeon. Amanda is a graduate of the University of Kentucky College of Pharmacy and her responsibilities in the New Jersey office include clinical direction of virology accounts.

With over 25 years of experience in all facets of pharmaceutical marketing research, Basya's background is ideally suited to lead Ziment's qualitative services division. She is an industry leader who has participated and helped shape the pharmaceutical marketing research industry as it has matured to what it is today. Prior to joining Ziment, Basya's primary supplier side experience was with IMS Health Consulting for the past 13 years, where she led a team of researchers and analysts in consulting engagements that supported client decisions about licensing opportunities, portfolio development, brand management and product line strategies. Before that, Basya had a long tenure on the client side of the business, invaluable experience in shaping her views on how research is used. This is over a 10 year period in positions of increasing responsibility at Bristol Myers Squibb, Johnson & Johnson and AstraZeneca, culminating in her position as Senior Director of Marketing Research & Business Planning at Rhone-Poulenc Rorer, in charge of research worldwide. Her experience includes a wide span of treatment areas, including cardiovascular, diabetes, urology, infectious disease, dermatology, hematology, musculoskeletal, respiratory, CNS, bone metabolism, AIDS and oncology. A published author, Basya's articles have appeared in a variety of pharmaceutical journals, including, The Journal of Pharmaceutical Marketing & Management and Medical Marketing & Media. She has also been a speaker at IMS' Asthma Research Trends Seminar, Institute for International Research Conference, and International Business Communications Conference. She holds BA and Ph.D. degrees from The University of Michigan, and a MA degree from Cornell University.

Beth Prince has over 16 years of sales and marketing experience with ten years of focus in the Information Technology field. Beth re-joined Databranch in 2001 after working with Bristol Myers Squibb as a Territory Manager for the National Sales Group. Prior to her work as a Territory Manager, she worked for the Parke-Davis Division of Pfizer Pharmaceuticals as a Training and Development Specialist for Sales and Marketing. As Vice President, Beth is responsible for the overall sales and marketing initiatives for Databranch. She also manages the human resource department, customer service department, as well as accounting and office operations. Beth holds numerous certifications from Databranch partners such as Novell, Cisco and Westbrook Technologies. Beth graduated from Eastern Illinois University and is an active member of the Olean Rotary Club.

Dr. Brian Boyle is an associate professor of medicine (courtesy) in the department of International Medicine and Infectious Diseases at Weill Medical College of Cornell University, medical training chairman of the International Center for Equal Healthcare Access and medical editor of HIVandHepatitis.com. He is a specialist in treating HIV infection and AIDS and has acted as an investigator in numerous clinical trials. Dr. Boyle has authored and co-authored more than two hundred publications and abstracts relating to the treatment of HIV. Prior to entering into medicine, Dr. Boyle received his J.D. from Notre Dame Law School, and practiced civil litigation for nearly a decade. He then returned to school for his M.D. from Georgetown University School of Medicine, and completed his internship and residency at Georgetown University Medical Center. He is both board-certified in Internal Medicine and a member of the State Bar of Georgia. Dr. Boyle is funded by, or is affiliated with Bristol-Myers Squibb, Pfizer, Gilead Sciences, Tibotec/J&J, and Abbott Laboratories as a consultant or member of the speakers bureau.

Warren Merlino is the Executive Vice President and Managing Director Logistic Services of PROMOTECH. At PROMOTECH, Warren oversees a full suite of non- personal promotion services for the life sciences industry to include fulfillment, distribution, warehousing, direct mail, database management, tele-services, e-services, print center and direct mail services. In addition, Mr. Merlino serves on the inVentiv Selling Solutions Senior Management Team. With over 21 years of pharmaceutical sales and marketing experience at companies such as Bristol-Myers Squibb and Ciba-Geigy Pharmaceuticals (Novartis), Warren brings a strong skill set in strategic and tactical planning, logistics, marketing, sales, managed care, leadership training and development, and negotiations to PROMOTECH. During the course of his career, Mr. Merlino has had the opportunity to work closely with executives at every level within the health care arena. In his tenure with PROMOTECH, he has led the company through five major company expansions, including the latest, a new 100,000 sq ft. literature distribution center. These changes have enhanced the capabilities available to PROMOTECH clients and positioned this inVentiv division for continued revenue growth. Mr. Merlino earned a B.S. degree in Political Science from Eckerd College in St. Petersburg, Florida as well as an M.B.A. from Emory University in Atlanta, Georgia.

Vicki L. Sato, Ph.D., Lead Outside Director and Chair of Infinity's Compensation Committee, is currently a professor at Harvard University. From 1992 - 2005, Dr. Sato held various positions with Vertex Pharmaceuticals, Inc., a publicly traded pharmaceutical company, most recently serving as President from 2000 - 2005. Prior to joining Vertex Pharmaceuticals, Inc., from 1984 - 1992, Dr. Sato held various positions with Biogen, Inc., a publicly traded biotechnology company, most recently serving as Vice President of Research and a member of the Scientific Advisory Board. Since 1993, Dr. Sato has served on the Board of Tutors, Department of Biochemistry and Molecular Biology at Harvard University, and also served as an Assistant Professor and Associate Professor in the Department of Biology at Harvard University from 1975 - 1983. Dr. Sato is a business advisor to Atlas Ventures, a venture capital firm, and other enterprises in the biotechnology and pharmaceutical industries. Dr. Sato serves as an overseer of the Isabella Stewart Gardner Museum and is a trustee of Jose Mateo’s Ballet Theatre. Dr. Sato serves as a director of Bristol-Myers Squibb Company and Alnylam Pharmaceuticals, Inc., publicly traded biopharmaceutical companies, Perkin-Elmer, Inc., a diversified company with businesses in the life and analytical sciences and optoelectronics, and Avila Therapeutics, a private biotechnology company. Dr. Sato received an A.B. in Biology from Radcliffe College and an M.A. and Ph.D. in Biology from Harvard University.

John R. Gibson, MBChB, MRCP (UK), FRCP (Glasgow) is the Senior Vice President, Global Development at Allergan, Irvine, California. He also serves as Volunteer Clinical Professor of Dermatology, UCI, Irvine, California, and SUNY, Buffalo, New York. He received his medical degree from Glasgow University in 1973, and subsequently trained in general medicine, infectious diseases and pediatrics in Zimbabwe and the United Kingdom. Development as a Dermatologist occurred in parallel with an industry career. He was appointed Honorary Consultant Dermatologist at the Royal London Hospital, England in 1982. He has significant international (27 years) experience in all aspects of drug development with three major pharmaceutical companies (Wellcome, Bristol-Myers Squibb and Allergan); and a track record of product approvals worldwide in the fields of dermatology, ophthalmology and neurology, with additional experience in oncology, allergy and anti-infectives, including anti-virals. His passion for drug development and medicine remains powerfully intact.

Freeh brings 26 years of experience in federal law enforcement to his position as Chairman of URU Technology Incorporated, previously holding positions within the FBI and serving as a federal district court judge and federal attorney. President Clinton nominated Louis Freeh as the fifth Director of the Federal Bureau of Investigation in 1993 where he served until 2001. During this time, Freeh was successful in modernizing and restructuring the FBI to better handle the dramatic changes that were occurring in crime, terrorism, and national security. He championed the cause of cooperative law enforcement action at all levels: local, state, federal, and foreign, and played an integral role in helping to keep the FBI at the forefront of investigative techniques, particularly in the use of advanced technologies to fight the evolving area of cyber-crime. Director Freeh also spearheaded the effort by law enforcement to ensure its ability to carry out court-authorized electronic surveillance in major investigations affecting public safety and national security in the face of telecommunications advances. Some of Director Freeh's most noteworthy accomplishments during this period were: - Established the National Infrastructure Protection Center (NIPC) that monitors the dissemination of computer viruses, worms and other malicious programs and to warn the government and business computer users of these dangers. It relies on the assistance and cooperation of its partners including federal agencies, the private sector and state and local law enforcement agencies. - Prepared the Economic Espionage Act (EEA) in 1996, a statue that makes the theft or misappropriation of a trade secret a federal crime. The Act prescribes the various acts defined under economic espionage and addresses the U.S. national and economic aspects of crime. It also addresses the theft of trade secrets. - Architected the Healthcare Fraud Act that established and funded a national program to combat fraud and abuse committed against all health plans, both public and private. The Act helped coordinate federal, state and local law enforcement programs in order to control fraud abuse, conduct investigations, facilitate the enforcement of statutes and provide industry guidance and special fraud alerts. - Spearheaded the passage of the Communications Assistance for Law Enforcement Act (CALEA) in 1994 that authorized electronic surveillance capabilities for law enforcement. While Freeh served as FBI Director, the U.S. government reinforced its commitment to security and protection of its citizens. Recognizing that Human Intelligence (Humint) is becoming a critical element in defense of crime, terrorism and identity theft, Freeh increased the FBI budget by 58 percent and helped pass legislation that strengthened the nation's crime-fighting abilities, including instituting Anti-Terrorism laws.

Chief Operating Officer and Chief Financial Officer, Apollo Global, Inc. John Baule, Apollo Global's Chief Operating Officer and Chief Financial Officer, most recently served as the COO & CFO of publicly-traded K-12 Inc. During John's five years with K-12, the company quadrupled in size and he was instrumental in taking it public. Mr. Baule brings extensive international experience to Apollo Global as CFO of global-technology consulting firm Headstrong (previously James Martin & Co.) and with Bristol-Myers Squibb in the Philippines and Hong Kong. With a bachelor's degree from the John College of William & Mary, Mr. Baule began his career as an auditor with KPMG Peat Marwick.